INT23105
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
Lymphomas of all cases were considered to have originated from B-cell lineage because their neoplastic cells expressed B1 (CD20) antigens. | |||||||||||||||
| |||||||||||||||
|
Another interesting therapeutic option is rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B-lymphocytes. | |||||||||||||||
| |||||||||||||||
|
These new therapies are: (1) "B lymphocyte (BL)" inhibitors such as anti-CD20 monoclonal antibody, anti-CD22 monoclonal antibody, BlyS antagonists, tolerogens of pathogenic-antibody secreting LB (LJP 394) and edratide; (2) "Inhibitors of the costimulation" between antigen-presenting cells and T lymphocyte (TL) like monoclonal anti-CD40 ligand antibody or CTLA-4-Ig (abatacept); (3) "Cytokine antagonists" inhibiting key cytokines of SLE: interleukin-10, interferon-alpha, interleukin-6 and TNF. | |||||||||||||||
| |||||||||||||||
|
B cell depletion via the anti-CD20 rituximab (Roche, Basel, Switzerland) was not successful in EXPLORER or LUNAR "generalized lupus" or nephritis-specific designed studies where all patients were given high doses of corticosteroids and immune suppressives as well [17,18]. | |||||||||||||||
| |||||||||||||||
|
Lymphomas of all cases were considered to have originated from B-cell lineage because their neoplastic cells expressed B1 (CD20) antigens. | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.